Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel Combined With Abiraterone in mCRPC
NCT01511536Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2012
- Primary completion
- Jul 2014
- Modality
- Allosteric Modulators
- Countries
- 3
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Mar 2012; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01511536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511536.